Neuropeptide
Semax 10mg
Buy Semax 10mg in Australia — >99.1% HPLC tested with batch-specific COA. Same-day Australian dispatch.
Synthetic ACTH(4-7) analogue research compound. Heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) with C-terminal Pro-Gly-Pro extension. Investigated in BDNF expression, dopaminergic, and serotonergic signalling models.
Institutional pricing
Volume pricing applies automatically at checkout when commerce is live. For bulk institutional orders or custom quantities, contact pillarresearch@pm.me.
Semax 10mg
Estimated launch price: $65 AUD
Add to cart is unavailable until launch. Enter your email and we'll notify you the moment Semax 10mg is in stock.
No spam. Unsubscribe anytime. For research use only.
Researchers studying Semax frequently study
Semax Overview
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) constructed from the ACTH(4-7) sequence with a C-terminal Pro-Gly-Pro extension. The extension confers resistance to enzymatic degradation. Originally developed in Russia, the compound has been studied extensively in neurotrophic and neuroprotective research models.
History
Semax was developed at Moscow State University in the 1980s as part of regulatory peptide research targeting the ACTH(4-10) fragment. The Pro-Gly-Pro extension was engineered to confer protease resistance, making the compound a useful research tool for neuropeptide signalling.
Semax Structure
Research Findings
Semax has been investigated in BDNF expression studies, dopaminergic signalling research, and serotonergic system modulation. Published preclinical literature includes neuroprotective, cognitive, and behavioural research models.
Key Areas of Research:
- •BDNF: Brain-derived neurotrophic factor expression studies
- •Dopaminergic: Dopamine system signalling research
- •Serotonergic: Serotonin system modulation
- •Neuroprotection: Preclinical neuroprotective models
References
References are provided for research context. Pillar Research does not endorse or interpret published findings as therapeutic claims.
Semax 10mg — research questions
Common questions for Australian researchers about Semax 10mg.
What is Semax?
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4-7) fragment with a C-terminal Pro-Gly-Pro extension. It is supplied as an investigational research compound for in vitro laboratory research under the RUO framework.
What is Semax used for in research?
Semax is investigated in BDNF (brain-derived neurotrophic factor) expression studies, dopaminergic signalling research, and serotonergic system modulation in preclinical models.
Why does Semax have a Pro-Gly-Pro extension?
The C-terminal Pro-Gly-Pro extension confers resistance to enzymatic degradation, extending the active half-life relative to the parent ACTH(4-7) fragment.
Is Semax legal in Australia?
Semax is classified as Schedule 4 (prescription-only) under the Australian Poisons Standard. It can be lawfully supplied for in vitro research purposes under the Research Use Only (RUO) framework. It is not listed on the Australian Register of Therapeutic Goods (ARTG) and is not a therapeutic good under the Therapeutic Goods Act 1989 (Cth).
How is Semax verified by Pillar Research?
Every batch is independently HPLC and mass spectrometry verified by a third-party Australian laboratory. The batch-specific Certificate of Analysis is downloadable from this page.
How should Semax be stored?
Store lyophilised vials at 2–8 °C, protected from light and moisture, in the original sealed vial. After reconstitution, store at 2–8 °C for short-term use or −20 °C for longer storage. Avoid repeated freeze–thaw cycles.